
Sandoz, the generics unit of Swiss drug major Novartis (NOVN: VX), has initiated a Phase III clinical trial with its biosimilar version of US drugmaker AbbVie’s (NYSE: ABBV) Humira (adalimumab).
Humira, the leading treatment of several autoimmune conditions including rheumatoid arthritis, psoriasis, and Crohn's disease, has overtaken Pfizer’s now off-patent Lipitor (atorvastatin) as the world’s best-selling drug, with 2013 sales expected to exceed $10 billion and forecast to reach $13 billion in 2016, the end of which the drug starts losing patent protection.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze